2015
Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer
Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer. Journal Of The National Cancer Institute 2015, 107: djv136. PMID: 25991002, PMCID: PMC4554192, DOI: 10.1093/jnci/djv136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantClinical Trials as TopicDisease-Free SurvivalExtracellular SpaceFemaleFluorescent Antibody TechniqueGene Expression Regulation, NeoplasticHumansIntracellular SpaceKaplan-Meier EstimateMiddle AgedPredictive Value of TestsPrognosisReceptor, ErbB-2Sensitivity and SpecificityTissue Array AnalysisTrastuzumabTreatment OutcomeConceptsHuman epidermal growth factor receptor 2ECD expressionICD statusLonger DFSQuantitative immunofluorescenceTrastuzumab therapyPrognostic valueBreast cancerTissue microarrayEpidermal growth factor receptor 2Adjuvant trastuzumab therapyDisease-free survival analysisTrastuzumab-treated patientsGrowth factor receptor 2High positive predictive valueHER2-positive tumorsKaplan-Meier estimatesFactor receptor 2ERBB2 gene amplificationHER2 protein expressionPositive predictive valueExtracellular domainAdjuvant chemotherapyHER2-ICDBetter DFS
2006
Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapy
Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M. Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapy. Cancer 2006, 109: 496-501. PMID: 17149760, DOI: 10.1002/cncr.22418.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularCyclophosphamideEpirubicinFemaleFluorouracilHumansKineticsMiddle AgedNeoadjuvant TherapyPrognosisProspective StudiesReceptor, ErbB-2TrastuzumabConceptsPrimary breast cancerPathological complete responseBreast cancerECD levelsPrimary chemotherapyNeoadjuvant therapyPathological responseWeek 6HER-2 extracellular domainWeek 3HER-2/neu receptorCycles of fluorouracilCycles of paclitaxelNeu extracellular domainTrastuzumab-based regimensUtility of quantitationInitiation of chemotherapyExtracellular domainSame chemotherapyWeekly trastuzumabInitial chemotherapyNeoadjuvant chemotherapyComplete responseTreatment regimenResidual disease
1999
Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c‐erbB‐2 (HER‐2/neu) gene product p185
Boyer C, Pusztai L, Wiener J, Xu F, Dean G, Bast B, O'Briant K, Greenwald M, DeSombre K, Bast R. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c‐erbB‐2 (HER‐2/neu) gene product p185. International Journal Of Cancer 1999, 82: 525-531. PMID: 10404066, DOI: 10.1002/(sici)1097-0215(19990812)82:4<525::aid-ijc10>3.0.co;2-j.Peer-Reviewed Original ResearchConceptsDifferent epitopesHER-2 receptorBreast cancer cell linesHER-2/neu geneRelative cytotoxic activityCytotoxic activityCancer cell linesEpitope targetsImmunotoxin therapyC-erbBImmunoglobulin isotypesUnconjugated antibodyEffective immunotoxinsExtracellular domainClonogenic assayImmunotoxinEpitope expressionNeu geneCompetitive binding assaysAntibodiesEpitopesAntibody bindingCell linesReceptorsBinding assays